K4 Elite
K4 Elite
A 33-residue recombinant analog of human glucagon-like peptide-2 with a Gly2 substitution, studied in models of intestinal epithelial growth, crypt stem cell survival and mucosal integrity.
Teduglutide is a recombinant 33-amino-acid analog of human glucagon-like peptide-2 (GLP-2), an intestinotrophic hormone released from enteroendocrine L-cells. It differs from native GLP-2 by a single substitution of glycine for alanine at position 2 [2].
That single change matters because alanine at position 2 is the cleavage site for dipeptidyl peptidase-4 (DPP-4). Native GLP-2 has a reported circulating half-life near 7 minutes, whereas the Gly2 analog is described in the literature as DPP-4-resistant with a half-life on the order of 2 hours [2].
It received a centralized European marketing authorization in August 2012 (Revestive) and U.S. FDA approval in December 2012 (Gattex) for short bowel syndrome with parenteral support dependence. It is the reference GLP-2 receptor agonist in gastrointestinal research [4].
Teduglutide binds the GLP-2 receptor, a class B GPCR expressed on subepithelial myofibroblasts, enteric neurons and enteroendocrine cells rather than directly on enterocytes. Signaling is therefore described as indirect, propagating to the crypt epithelium through mediators including IGF-1, ErbB ligands and keratinocyte growth factor [3].
Study reports attribute the increases in villus height, crypt depth and mucosal mass observed in animal models to enhanced crypt cell proliferation together with reduced enterocyte apoptosis downstream of that signaling [1][3].
In a radiation-injury model, investigators administered teduglutide ([Gly2]GLP-2) to mice around whole-body irradiation and used crypt microcolony and lineage-tracing assays to measure survival of Lgr5+ small intestinal stem cells, reporting greater crypt survival in treated animals than in irradiated controls [1].
In BDF1 mice, 14 days of subcutaneous native GLP-2 or teduglutide was reported to increase small-intestinal weight by approximately 28 percent, with comparable increases in crypt size, villus height and mucosal area between the native peptide and the analog [2].
In rats maintained on total parenteral nutrition, combined administration of EGF and GLP-2 produced additive increases in small-intestinal weight and crypt cell proliferation relative to either factor alone, which investigators used to map receptor cross-talk in the crypt compartment [3].
A systematic review and meta-analysis pooled randomized and observational short bowel syndrome studies, with reduction in parenteral support volume as the primary aggregated endpoint; the authors noted substantial heterogeneity across study designs and populations [4].
Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.